Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials. // The Lancet. – URL: https://www.sciencedirect.com/science/article/pii/S0140673626020581?dgcid=rss_sd_all
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials. The Lancet. https://www.sciencedirect.com/science/article/pii/S0140673626020581?dgcid=rss_sd_all
“Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.” The Lancet.
@article{article148522,
title = {Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials},
journal = {The Lancet},
url = {https://www.sciencedirect.com/science/article/pii/S0140673626020581?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...